Unusual presentation of
Molecular testing
NSCLC
ROS1 rearrangement
Targeted therapies
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
05
2024
revised:
14
08
2024
accepted:
14
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
The spectrum of clinical and radiographic presentations of lung adenocarcinoma is increasingly broad, including in the metastatic setting. Here, we report on a patient who initially presented with a mild chronic cough that remained stable over a decade, with serial CT scans showing gradual worsening of multifocal areas of consolidation and ground-glass opacities of the bilateral lungs. The patient was ultimately diagnosed with
Identifiants
pubmed: 39257471
doi: 10.1016/j.rmcr.2024.102091
pii: S2213-0071(24)00114-X
pmc: PMC11386496
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
102091Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Catherine Shu reports a relationship with Arcus Biosciences Inc that includes: consulting or advisory. Catherine Shu reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. Catherine Shu reports a relationship with Genentech that includes: consulting or advisory. Catherine Shu reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Catherine Shu reports a relationship with Beth Israel Deaconess Medical Center that includes: consulting or advisory. Catherine Shu reports a relationship with Takeda that includes: consulting or advisory. Catherine Shu reports a relationship with Gilead that includes: consulting or advisory If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Anjali Saqi reports a consulting/advisory relationship with the following: Veracyte, Boehringer Ingelheim, Genentech, Roche, Bristol Myers Squibb, Abbvie, Fieldworks, Medscape, Dedham, Qessential, Noreen Ellis, PeerView, Gilead.